Tue Jul 15 03:20:00 UTC 2025: Okay, here’s a news article summarizing the information provided:

**News Article:**

**Anthem Biosciences Launches ₹3,395 Crore IPO, Subscription Opens Today**

**Bengaluru, India – July 14, 2025** – Anthem Biosciences, a leading Indian Contract Research, Development & Manufacturing Organization (CRDMO), has launched its initial public offering (IPO) today, July 14, 2025. The IPO, a complete offer for sale (OFS) of 5.96 crore shares, aims to raise ₹3,395.00 crores.

The IPO’s price band is set at ₹540 to ₹570 per share. Investors can apply for a minimum lot size of 26 shares, requiring a minimum investment of ₹14,040. The subscription window will remain open until July 16, 2025.

The allotment process is expected to be finalized on July 17, 2025, with a tentative listing date of July 21, 2025, on both the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE).

JM Financial Limited, Citigroup Global Markets India, J P Morgan India, and Nomura Financial Advisory and Securities (India) Pvt Ltd are serving as the book-running lead managers for the issue. Kfin Technologies Limited is the registrar.

On the first day of subscription, the IPO was subscribed 0.77 times overall. Retail investors subscribed 0.62 times, Qualified Institutional Buyers (QIBs) subscribed 0.39 times, and Non-Institutional Investors (NIIs) subscribed 1.64 times.

Anthem Biosciences will not receive any proceeds from the IPO, as the entire amount will go to the promoter selling shareholder, after deducting offer-related expenses and taxes.

According to a Business Standard media report, the Grey Market Premium (GMP) for Anthem Biosciences shares is currently ₹100. This suggests a potential listing price of around ₹670 per share, based on the upper end of the price band, indicating a potential gain of 17.5%.

Founded in 2006 and based in Bengaluru, Anthem Biosciences offers comprehensive services across drug discovery, development, and manufacturing, catering to over 550 clients in 44 countries, including major regulated markets such as the US, Europe, and Japan. The company reported revenue of ₹1,844.6 crore and a net profit of ₹451.3 crore in FY25.

**Disclaimer:** *Investors are advised to conduct their own research before making any investment decisions. Grey Market Premium (GMP) is an unauthenticated market-related news and should be considered for informational purposes only.*

**Summary:**

Anthem Biosciences launched its ₹3,395 Crore IPO on July 14, 2025, with a price band of ₹540-₹570. The IPO is an OFS and closes on July 16th, with listing expected on July 21st. Subscription on Day 1 was 0.77x. GMP suggests a potential listing gain of 17.5%. Anthem Biosciences is a leading Indian CRDMO with strong financials.

Read More